Overview

Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

Phase:

Phase 2

Details

Lead Sponsor:

Alain Algazi

Collaborator:

Genentech, Inc.

Treatments:

Atezolizumab